Search

Your search keyword '"Contraceptive drug implants -- Product development"' showing total 13 results
Start Over Descriptor "Contraceptive drug implants -- Product development"
13 results on '"Contraceptive drug implants -- Product development"'

1. Agile Therapeutics Announces Peer-Reviewed Publication of Phase 3 SECURE Study Results for Twirla(R) (levonorgestrel and ethinyl estradiol) Transdermal System in Contraception

Subjects
Agile Therapeutics Inc. -- Product development, Estradiol -- Product development, Contraceptive drug implants -- Product development, Phenols -- Product development, Levonorgestrel -- Product development, Ethinyl estradiol -- Product development, Reproductive health, Contraception, Pharmaceutical industry -- Product development, Banking, finance and accounting industries, Business, Twirla (Contraceptive) -- Product development
Abstract

PRINCETON, N.J., Dec 01, 2020 (GLOBE NEWSWIRE via COMTEX) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Contraception, an international, peer-reviewed, reproductive health journal, published [...]

Published
2020

2. Agile Therapeutics Announces Peer-Reviewed Publication of Phase 3 SECURE Study Results for Twirla (levonorgestrel and ethinyl estradiol) Transdermal System in Contraception

Subjects
Agile Therapeutics Inc. -- Product development, Contraceptive drug implants -- Product development, Estradiol -- Product development, Contraception, Reproductive health, Pharmaceutical industry -- Product development, Levonorgestrel -- Product development, Ethinyl estradiol -- Product development, Phenols (Class of compounds) -- Product development, Business, international, Law, Twirla (Contraceptive) -- Product development
Abstract

(GlobeNewswire) - Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Contraception, an international, peer-reviewed, reproductive health journal, published the primary safety, efficacy, and tolerability results from [...]

Published
2020

3. Studies from University of Helsinki Provide New Data on Clinical Trials and Studies (Fast-track vs. delayed insertion of the levonorgestrel-releasing intrauterine system after early medical abortion - a randomized trial)

Subjects
Clinical trials, Contraceptive drug implants -- Product development, Physical fitness, Medical research, Abortion, Levonorgestrel -- Research -- Product development, Health, University of Helsinki
Abstract

2017 NOV 25 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on Clinical Research - Clinical Trials and Studies have [...]

Published
2017

4. Newly Published Data from Phase 3 Clinical Trial of LILETTA(r) (levonorgestrel-releasing intrauterine system) 52 mg Confirms Efficacy, Safety, and Tolerability Through Five Years

Subjects
Levonorgestrel -- Product development, Clinical trials, Contraceptive drug implants -- Product development, Women's health, Contraceptives, Pharmaceutical industry, Obstetrics, General interest, News, opinion and commentary
Abstract

SAN FRANCISCO: Medicines360 has issued the following news release:Medicines360, a global nonprofit women's health pharmaceutical company, announced newly published data finding that LILETTA is highly efficacious in preventing pregnancy over [...]

Published
2018

5. Newly Published Data from Phase 3 Clinical Trial of LILETTA (levonorgestrel-releasing intrauterine system) 52 mg Confirms Efficacy, Safety, and Tolerability Through Five Years

Subjects
Women -- Health aspects, Contraceptive drug implants -- Product development, Levonorgestrel -- Product development, Clinical trials, Business, News, opinion and commentary
Abstract

Data from ACCESS IUS, the largest ongoing Phase 3 clinical trial in the U.S. of an intrauterine system evaluating pregnancy prevention, also reports bleeding profile over five years in diverse [...]

Published
2018

6. Male contraceptive shows promise

Author

Larkin, Marilynn

Subjects
Male contraceptives -- Product development, Contraceptive drug implants -- Product development
Published
2000

7. Medicines360 and Allergan Present Four-Year Multi-Center Pivotal Trial Data of LILETTA (levonorgestrel-releasing intrauterine system) 52 mg at the 2017 ACOG Meeting

Subjects
Women -- Health aspects, Pregnancy, Contraceptive drug implants -- Product development, Levonorgestrel -- Product development, Business, News, opinion and commentary, American College of Obstetricians and Gynecologists
Abstract

DUBLIN and SAN FRANCISCO, May 9, 2017 /PRNewswire/ -- Allergan plc (NYSE:AGN), a leading global pharmaceutical company, and Medicines360, a nonprofit women's health pharmaceutical company with a mission of expanding [...]

Published
2017

8. Beyond the Pill

Author

Brink, Susan

Subjects
Birth control -- Product development, Pharmaceutical industry -- Product development, Women -- Health aspects, Contraceptives industry -- Product development, Contraceptive drugs, Injectable -- Product development, Contraceptive drug implants -- Product development
Published
2002

9. Other approaches to birth control

Subjects
Conceptus Inc. -- Product development, Pharmacia Corp. -- Product development, Intrauterine contraceptives -- Product development, Contraceptive drug implants -- Product development, Contraceptives industry -- Product development, Health
Abstract

There are two new intrauterine devices that promise to be better tolerated and as efficacious as the IUDs currently in use. Mirena is a hormone-containing rod that prevents pregnancy in [...]

Published
2000

10. Implanon status report: Not on U.S. market yet

Subjects
Contraceptive drug implants -- Product development, Health
Abstract

A new single-rod progestin contraceptive implant from Netherlands-based Organon NV is poised for market introduction in the United Kingdom and the Netherlands, and it may enter the approval process soon [...]

Published
1999

11. Studies from Cheng Hsin General Hospital Have Provided New Information about Clinical Trials and Studies (Postoperative maintenance levonorgestrel-releasing intrauterine system and endometrioma recurrence: a randomized controlled study)

Subjects
Clinical trials, Contraceptive drug implants -- Product development, Medical research, Levonorgestrel -- Research -- Product development, Health, Health care industry
Abstract

2017 AUG 13 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Devices & Surgical Technology Week -- Data detailed on Clinical Research - Clinical Trials and Studies have [...]

Published
2017

12. Capsules; Flaxseed May Limit Prostate Tumors

Author

Maugh, Thomas H., II

Subjects
Flaxseed -- Health aspects, Prostate cancer -- Prevention, Male contraceptives -- Product development, Contraceptive drug implants -- Product development, Left- and right-handedness -- Health aspects, Inflammatory bowel diseases -- Risk factors, Ulcers -- Care and treatment, Electric stimulation -- Health aspects, General interest, News, opinion and commentary
Published
2001

13. The chill in birth control research

Author

Roan, Shari

Subjects
Wyeth-Ayerst Laboratories -- Product development -- 00111989, Norplant (Contraceptive) -- Research, Pharmaceutical industry -- Product development, Contraceptives industry -- Research, Contraceptive drug implants -- Product development
Published
1998

Catalog

Books, media, physical & digital resources
See catalog results